retatrutide phase 2 nejm weight loss 48 weeks Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide dose: the complete guide

What kind of weight you lose matters enormously

Researchers interested in sequential protocols should consult the peptide stacking guide for current evidence on sequential agonist approaches and the peptide cycling guide for washout period recommendations

Cui et al

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide carry the clinical evidence: STEP for semaglutide ( The New England Journal of Medicine , 2021), SURMOUNT for tirzepatide (NEJM, 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM, 2024)

Source drops from a reputable compounding pharmacy with appropriate accreditation and the ability to provide certificates of analysis